Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Authors : Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A
Year : 2017
Journal : Clin Cancer Res
Volume : 23(21)
Pages : 6411-6420

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Authors : Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, OShaughnessy J
Year : 2017
Journal : Breast Cancer Res Treat
Volume : 166(1)
Pages : 327-328

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.

Authors : Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2219-2224

The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.

Authors : Kourie HR, Awada G, Awada A
Year : 2017
Journal : Immunotherapy
Volume : 9
Pages : 647-657

How to emerge from the conservatism in clinical research methodology?

Authors : Kotecki N, Penel N, Awada A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29(5)
Pages : 400-404

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study

Authors : Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenar E, Degardin M, Pateras IS, Langendijk JA, Van Herpen C, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB
Year : 2017
Journal : Ann Oncol
Volume : 28(9)
Pages : 2213-2218

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Authors : Najem A, Krayem M, Sales F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem G
Year : 2017
Journal : Eur J Cancer
Volume : 83
Pages : 154-165

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors : Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M
Year : 2017
Journal : Lancet Oncol
Volume : 18(7)
Pages : 904-916

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Authors : Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, OShaughnessy J
Year : 2017
Journal : Breast Cancer Res Treat
Volume : 166(1)
Pages : 327-8

Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art.

Authors : Lambertini M, Goldrat O, Clatot F, Demeestere I, Awada A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29(4)
Pages : 243-252

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Authors : Twelves C, Cortés J, OShaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS
Year : 2017
Journal : Eur J Cancer
Volume : 76
Pages : 205-215

Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.

Authors : Kourie HR, Kanaan H, Awada G, Awada A
Year : 2017
Journal : Future Oncol
Volume : 13(12)
Pages : 1097-1103

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Authors : Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS
Year : 2017
Journal : Breast Cancer Res Treat
Volume : 163(3)
Pages : 535-544

The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges.

Authors : Solinas C, Chanzá NM, Awada A, Scartozzi M
Year : 2017
Journal : Cancer Treat Rev
Volume : 53
Pages : 138-145

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Authors : Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G
Year : 2017
Journal : Oncotarget
Volume : 8(2)
Pages : 2320-2328

Advances in chemical pharmacotherapy to manage advanced breast cancer.

Authors : Gombos A, Awada A
Year : 2017
Journal : Expert Opin Pharmacother
Volume : 18
Pages : 95-103

Systemic chemotherapy regimens in early breast cancer patients: updated recommendations from the BSMO breast cancer task force.

Authors : Wildiers H, Duhoux F, Awada A, de Azambuja E
Year : 2017
Journal : Belgian J Medical Oncology
Volume : 11(8)
Pages : 375-379

Extra-osseous Ewing sarcoma of the thyroid gland mimicking a hemorrhagic cyst of Hashimoto thyroiditis

Authors : El Hachem G, Jungels C, de Saint-Aubain de Somerhausen N, Awada A, Gil T
Year : 2017
Journal : Journal of clinical reviews and case reports
Volume : 1(1)
Pages : -

PRIMA-1 and PRIMA-1 Met(APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Authors : Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M
Year : 2017
Journal : Cancers (Basel)
Volume : 9

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Authors : Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2017
Journal : Front Immunol
Volume : 8
Pages : 1412